Basic Information
| RNALocate ID: | RLID:11000915 |
| RNA Symbol: | hsa-miR-30a-3p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-30a-3p |
| RNA ID: | miRBase:MIMAT0000088 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001384 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001385 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:11000914 | Exosome | Brain tissue | 23382797 |
| RLID:11000916 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11000917 | Microvesicle | Follicular fluid | 23666971 |
| RLID:11000918 | Microvesicle | Serum | 24797360 |
| RLID-D:11000024 | Exosome | Breast milk|Endothelial cells|Epithelial cells|Tongue tissue | |
| RLID-D:11000287 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-30a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-36588 |
| MNDR | hsa-miR-30a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-36589 |
| MNDR | hsa-miR-30a-3p | Oral squamous cell carcinoma | MNDR-E-MI-36590 |
| MNDR | hsa-miR-30a-3p | Large cell neuroendocrine cancer | MNDR-E-MI-36591 |
| MNDR | hsa-miR-30a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-36592 |
| MNDR | hsa-miR-30a-3p | Lymphoma | MNDR-E-MI-36593 |
| MNDR | hsa-miR-30a-3p | Lymphoma non-hodgkin | MNDR-E-MI-36594 |
| MNDR | hsa-miR-30a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-36595 |
| MNDR | hsa-miR-30a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-36596 |
| MNDR | hsa-miR-30a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-36597 |
| MNDR | hsa-miR-30a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-36598 |
| MNDR | hsa-miR-30a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-36599 |
| MNDR | hsa-miR-30a-3p | Niemann-pick disease type c | MNDR-E-MI-36600 |
| MNDR | hsa-miR-30a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-36601 |
| MNDR | hsa-miR-30a-3p | Autosomal recessive limb-girdle muscular dystrophy type 2a | MNDR-E-MI-36602 |
| MNDR | hsa-miR-30a-3p | Dermatomyositis | MNDR-E-MI-36603 |
| MNDR | hsa-miR-30a-3p | Prostate cancer | MNDR-E-MI-36604 |
| MNDR | hsa-miR-30a-3p | Gastric cancer | MNDR-E-MI-36605 |
| MNDR | hsa-miR-30a-3p | Gastric lymphoma | MNDR-E-MI-36606 |
| MNDR | hsa-miR-30a-3p | Alzheimer disease | MNDR-E-MI-36607 |
| MNDR | hsa-miR-30a-3p | Bladder cancer | MNDR-E-MI-36608 |
| MNDR | hsa-miR-30a-3p | Esophageal carcinoma | MNDR-E-MI-36609 |
| MNDR | hsa-miR-30a-3p | Distal muscular dystrophy | MNDR-E-MI-36610 |
| MNDR | hsa-miR-30a-3p | Duchenne muscular dystrophy | MNDR-E-MI-36611 |
| MNDR | hsa-miR-30a-3p | Seizures | MNDR-E-MI-36612 |
| MNDR | hsa-miR-30a-3p | Head and neck cancer | MNDR-E-MI-36613 |
| MNDR | hsa-miR-30a-3p | Huntington disease | MNDR-E-MI-36614 |
| MNDR | hsa-miR-30a-3p | Cardiovascular disease | MNDR-E-MI-36615 |
| MNDR | hsa-miR-30a-3p | Lung cancer | MNDR-E-MI-36616 |
| MNDR | hsa-miR-30a-3p | Parkinson disease | MNDR-E-MI-36617 |
| MNDR | hsa-miR-30a-3p | Niemann-pick disease | MNDR-E-MI-36618 |
| MNDR | hsa-miR-30a-3p | Basal-like breast cancer | MNDR-E-MI-36619 |
| MNDR | hsa-miR-30a-3p | Thyroid cancer | MNDR-E-MI-36620 |
| MNDR | hsa-miR-30a-3p | Pancreatic cancer | MNDR-E-MI-36621 |
| MNDR | hsa-miR-30a-3p | Melanoma | MNDR-E-MI-36622 |
| MNDR | hsa-miR-30a-3p | Rectum adenocarcinoma | MNDR-E-MI-36623 |
| MNDR | hsa-miR-30a-3p | Nephroblastoma | MNDR-E-MI-36624 |
| MNDR | hsa-miR-30a-3p | Colon cancer | MNDR-E-MI-36625 |
| MNDR | hsa-miR-30a-3p | Ischemic attack transient | MNDR-E-MI-36626 |
| MNDR | hsa-miR-30a-3p | Colon adenocarcinoma | MNDR-E-MI-36627 |
| MNDR | hsa-miR-30a-3p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-36628 |
| MNDR | hsa-miR-30a-3p | Familial ovarian cancer | MNDR-E-MI-36629 |
| MNDR | hsa-miR-30a-3p | Prostate adenocarcinoma | MNDR-E-MI-36630 |
| MNDR | hsa-miR-30a-3p | Kidney cancer | MNDR-E-MI-36631 |
| MNDR | hsa-miR-30a-3p | Carcinoma ductal breast | MNDR-E-MI-36632 |
| MNDR | hsa-miR-30a-3p | Glioblastoma | MNDR-E-MI-36633 |
| MNDR | hsa-miR-30a-3p | Malignant glioma | MNDR-E-MI-36634 |
| MNDR | hsa-miR-30a-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-36635 |
| MNDR | hsa-miR-30a-3p | Nemaline myopathy | MNDR-E-MI-36636 |
| MNDR | hsa-miR-30a-3p | Inclusion body myositis | MNDR-E-MI-36637 |
| MNDR | hsa-miR-30a-3p | Infarction middle cerebral artery | MNDR-E-MI-36638 |
| MNDR | hsa-miR-30a-3p | Meningioma | MNDR-E-MI-36639 |
| MNDR | hsa-miR-30a-3p | Gastric adenocarcinoma | MNDR-E-MI-36640 |
| MNDR | hsa-miR-30a-3p | Lung squamous cell carcinoma | MNDR-E-MI-36641 |
| MNDR | hsa-miR-30a-3p | Lung adenocarcinoma | MNDR-E-MI-36642 |
| MNDR | hsa-miR-30a-3p | Adrenocortical cancer | MNDR-E-MI-36643 |
| MNDR | hsa-miR-30a-3p | Thyroid carcinoma | MNDR-E-MI-36644 |
| MNDR | hsa-miR-30a-3p | Bladder urothelial carcinoma | MNDR-E-MI-36645 |
| MNDR | hsa-miR-30a-3p | Pancreatic adenocarcinoma | MNDR-E-MI-36646 |
| MNDR | hsa-miR-30a-3p | Carcinoma renal cell | MNDR-E-MI-36647 |
| MNDR | hsa-miR-30a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-36648 |
| MNDR | hsa-miR-30a-3p | Large cell carcinoma | MNDR-E-MI-36649 |
| MNDR | hsa-miR-30a-3p | Esophageal cancer | MNDR-E-MI-36650 |
| MNDR | hsa-miR-30a-3p | Lung small cell carcinoma | MNDR-E-MI-36651 |
| MNDR | hsa-miR-30a-3p | Synovial sarcoma | MNDR-E-MI-36652 |
| MNDR | hsa-miR-30a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-36653 |
| MNDR | hsa-miR-30a-3p | Breast invasive carcinoma | MNDR-E-MI-36654 |
| MNDR | hsa-miR-30a-3p | Hepatocellular carcinoma | MNDR-E-MI-36655 |
| MNDR | hsa-miR-30a-3p | Embryonal cancer | MNDR-E-MI-36656 |
| MNDR | hsa-miR-30a-3p | Familiar ovarian carcinoma | MNDR-E-MI-36657 |
| MNDR | hsa-miR-30a-3p | B-cell lymphoma | MNDR-E-MI-36658 |
| MNDR | hsa-miR-30a-3p | Rheumatoid arthritis | MNDR-E-MI-36659 |
| MNDR | hsa-miR-30a-3p | Hodgkin lymphoma | MNDR-E-MI-36660 |
| MNDR | hsa-miR-30a-3p | Burkitt lymphoma | MNDR-E-MI-36661 |
| MNDR | hsa-miR-30a-3p | Skin cutaneous melanoma | MNDR-E-MI-36662 |
| MNDR | hsa-miR-30a-3p | Skin melanoma | MNDR-E-MI-36663 |
| MNDR | hsa-miR-30a-3p | Acute myeloid leukemia | MNDR-E-MI-36664 |
| MNDR | hsa-miR-30a-3p | Colorectal cancer | MNDR-E-MI-36665 |
| MNDR | hsa-miR-30a-3p | Nasopharynx carcinoma | MNDR-E-MI-36666 |
| MNDR | hsa-miR-30a-3p | Acute lymphocytic leukemia | MNDR-E-MI-36667 |
| MNDR | hsa-miR-30a-3p | Cardiomegaly | MNDR-E-MI-36668 |
| MNDR | hsa-miR-30a-3p | Nasopharyngeal cancer | MNDR-E-MI-36669 |
| MNDR | hsa-miR-30a-3p | Prostatic neoplasms | MNDR-E-MI-36670 |
| MNDR | hsa-miR-30a-3p | Polymyositis | MNDR-E-MI-36671 |
| MNDR | hsa-miR-30a-3p | Peripheral nerve injuries | MNDR-E-MI-36672 |
| MNDR | hsa-miR-30a-3p | Chronic pain | MNDR-E-MI-36673 |
| MNDR | hsa-miR-30a-3p | Breast cancer her3+ negative | MNDR-E-MI-36674 |
| MNDR | hsa-miR-30a-3p | Duke B | MNDR-E-MI-36675 |
| MNDR | hsa-miR-30a-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-36676 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ATF3 | Homo sapiens | RR00155507 |
TOP